Pomerantz LLP has announced a significant class action against Quantum Biopharma and financial giants to claim market manipulation
The Pomerantz Law Firm has formally announced the launch of a class action lawsuit on behalf of shareholders who have incurred losses in Quantum Biopharma Ltd., which is an important step for the securities litigation industry. The complaint alleges a sophisticated operation involving “spoofing” and market manipulation intended to deceive investors, and it targets both the corporation and several prominent financial institutions.
You can also read Deterministic Single Photon Sources in the Telecom C-Band
A Coordinated ‘Spoofing’ Scheme
The lawsuit, according to the legal complaint, is against numerous significant banking organizations as well as Quantum Biopharma’s officers and directors for their internal conduct. Among the defendants listed in the case are the Royal Bank of Canada, RBC Capital Markets, LLC, and CIBC World Markets, Inc.
According to the complaint, the allegation’s central claim is “spoofing.” These defendants allegedly entered thousands of sell orders that they never meant to carry out on multiple occasions. These transactions were intended to give the larger market the misleading impression that the price of Quantum shares was declining.
These manipulative strategies, according to the lawsuit, were successful in tricking other investors into selling their interests at inflatedly low prices. The defendants are accused of buying shares at these low prices after the market price had dropped due to this false pressure, setting themselves up to benefit at the expense of the class members who were “baited” into selling.
You can also read Bitcoin Quantum News: BTQ Launches Bitcoin Quantum Testnet
Important Deadlines for Investors Affected
A significant legal milestone is being alerted to investors who bought or acquired Quantum Biopharma securities within the designated Class Period. Petitioners must submit their petition by February 23, 2026, to be appointed as Lead Plaintiffs.
In class action lawsuits, a Lead Plaintiff plays a crucial role in representing the interests of all class members. It is possible for shareholders to participate in any possible recovery while being absent class members, even if they choose to be designated as Lead Plaintiffs.
Danielle Peyton is Pomerantz LLP’s designated point of contact for anyone looking to learn more or join the action. When contacting interested parties, it is advised that they include their mailing address, phone number, and the precise quantity of shares they have bought.
You can also read SEALSQ Presentation at the Needham Growth Conference 2026
A History of Securities Lawsuits
The lawsuit’s firm, Pomerantz LLP, has a long and illustrious history in both domestic and foreign law. Established by the late Abraham L. Pomerantz, who is frequently called the “dean of the class action bar,” the company was a trailblazer in the securities class action space.
After more than 85 years of operation, the company is still present throughout the world, with offices in New York, London, Paris, and Tel Aviv. Their practice is committed to defending the rights of people who have been harmed by corporate wrongdoing, securities fraud, and fiduciary obligation violations. In the past, the firm has been successful in helping its clients get multiple multimillion-dollar damages awards.
You can also read Quantum SDT Raises $20.6M for Hybrid AI–Quantum Computing
Extending the Focus: Examining Ventyx and ADC Therapeutics
Pomerantz’s attention is currently focused on more than only the Quantum Biopharma case. Concurrently, the firm has acknowledged that it is looking into allegations on behalf of investors in ADC Therapeutics SA and Ventyx Biosciences, Inc., two other publicly traded firms.
The firm is aggressively investigating possible claims of securities fraud or other illegal business practices, even if the specifics of the accusations against Ventyx and ADC Therapeutics were not fully revealed in the original alerts. A wider pattern of heightened examination of biopharmaceutical companies listed on major markets such as the NASDAQ and NYSE is suggested by these probes.
You can also read The MKS Inc. Advances Photonics for AI, Quantum, and Biotech
The Future Direction for Stockholders
The legal world will be keeping a careful eye on the Quantum Biopharma case as the deadline of February 23, 2026 draws near, especially considering the involvement of significant Canadian and foreign banks. The verdict in this case may have a big impact on how spoofing and algorithmic trading are regulated in the context of new biopharmaceutical stocks.
For the time being, it is recommended that stockholders examine their investment records. The firm has made it clear that some of its pronouncements could be construed as attorney advertising and that the Quantum, Ventyx, or ADC Therapeutics processes may not have the same outcome as previous successful outcomes in instances that are similar.
You can also read Kathy Hochul 2026 Quantum Corridor Plan For New York State
